Etctn P10500: Phase 1 Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory Lymphoma

• Published in: Blood 2024-11, Vol.144 (Supplement 1), p.3112-3112
• Main Authors: Amengual, Jennifer E., Tun, Aung M., Piorczynski, Ted B., Tiger, Yun Kyoung, Yazbeck, Victor, Cherng, Hua-Jay J, Tolu, Seda S., Pro, Barbara, Durecki, Diane, Beumer, Jan, Kelleher, Neil, Sender, Naomi, Sta Ana, Sarah, Kalia, Anxhela, Raposo Corradini, Beatriz, Shyr, Yu, LoRusso, Patricia, Pelosof, Lorraine, Piekarz, Richard
• Format: Article
• Language: English
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood-2024-199650

Given the critical importance of concurrent derangements in epigenetic modifiers (CREBBP, EP300, and EZH2) in germinal center (GC) B- and T-cell lymphomas, combined targeting of epigenetic machinery with tazemetostat (EZH2i) and belinostat (HDACi) may induce profound epigenetic modification, leading to the induction of cell death. Preclinical data generated in our lab has demonstrated that when combined in discrete subsets of DLBCL and T cell lymphomas, tazemetostat plus belinostat leads to highly synergistic interactions via modulation of both histone acetylation and methylation, leading to prolonged survival in murine models (Lue 2019). Based on these observations, the NCI/CTEP ETCTN P10500 clinical study was designed to study the combination of tazemetostat plus belinostat in R/R lymphoma (NCT05627245). Patients with R/R non-Hodgkin lymphoma were eligible for this open-label phase 1 study. Patients must not be eligible for ASCT and have adequate organ function. Patients were enrolled based on a standard 3-by-3 phase 1 design and treated on a 21-day cycle with tazemetostat orally twice daily at doses between 600-800 mg, and belinostat intravenous daily for 5 days between doses of 600-1000mg. The primary endpoint is to determine the maximum tolerated dose and the dose limiting toxicities to find recommended phase 2 dose. Safety was assessed according to CTCAE v5.1. DLTs were assessed within the first cycle. Patients were treated until unacceptable toxicity or progression. Response was assessed per Lugano criteria. The pharmacokinetic profile was determined for the combination and paired peripheral blood samples were evaluated for T cell activation. As of July 30, 2024, 11 patients were enrolled (DLBCL n=1, transformed DLBCL n=2, TCL n=7, PTLD/HGBCL n=1) across 3 dose cohorts (n=6 dose level (DL) 1, n=3 DL2, n=2 DL3). Median age was 62 y (range 31-88), 8 were male; 8 were White Non-Hispanic, 1 White Hispanic, 2 Black. Median baseline performance status was 1, and Stage 1 n=1, Stage 3 n=3, Stage 4 n=6 (missing n=1). Median number of prior therapies was 4 (1-7), including prior autologous SCT n=4, allogeneic SCT n=1 and CAR T n=2. The median number of cycles received was 2.5 (1-12+). Reasons for discontinuation from study included transition to transplant (n=1), AE n=1, withdrawal of consent n=1, lack of clinical improvement despite SD n=1, and PD n=5. There was one DLT observed in DL1: grade 4 thrombocytopenia. It occurred in a heavily pretreated subject wi